Medscape: German Society Updates Rheumatic Diseases Guidelines in Light of SARS-CoV-2 Pandemic
UC rheumatologist discusses new guidance for treating rheumatic disease during COVID-19
Avis Ware, MD, director and professor in the UC Division of Allergy, Immunology and Rheumatology, spoke with Reuters Health for a story about the German Society for Rheumatology updating its guidelines to reflect the impact of the COVID-19 pandemic. A key change is a recommendation that anti-rheumatic medication should not be changed solely for fear of SARS-CoV-2 infection.
Other key findings include that patients with an inflammatory rheumatic disease (IRD) do not have a higher risk of contracting SARS-CoV-2 and that IRD patients should follow the same behavioral and precautionary measures as the general population. Ware told Reuters Health that many of the recommendations overlap with guidance from the American College of Rheumatology and the European League Against Rheumatism.
Read the full interview in Medscape online.
Learn more about Avis Ware, MD.
Featured image of Avis Ware, MD, taken by Colleen Kelley/UC Creative + Brand.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.